BioSpace News Archive

Otsuka America Pharmaceutical, Inc., (Otsuka) today announces that it has purchased the assets of Proteus Digital Health, Inc. (Proteus), including assets and intellectual property for its ingestible and wearable sensor technology.

Revel Health, a Minneapolis-based next-gen healthcare technology company, and Coriell Life Sciences (CLS), a Philadelphia-based bioinformatics company and leading provider of genetic interpretation and reporting, today announced a partnership designed to drive healthier action for Medicare Advantage members in relation to how their genes impact the effectiveness and efficacy of prescribed medications.

ExoCoBio Inc. announced that it recently raised $9.3 million in its series C and Pre-IPO funding. For this round, return VCs of K2 Investment Partners, SBI Investment Korea, and Dt & Investment were joined by new comers G.N.Tech/ReeHu Investment and Focus Assets Management.

The access information for the investor conference call remains as follows: Direct Toll / International – 1-(866) 831-8711 Domestic US/Canada - 1-(203) 518-9883 Program Title: Generex Biotechnology Conference Call Conference ID – 89636 Updated Agenda FDA response to Pre-IND briefing package for Ii-Key-SARS-CoV-2 vaccine Meeting with the Canadian National Research Council to discuss moving the Ii-Key-SARS-CoV-2 vaccine technology forward Completed the deal with Worldwide Digitech, LLC (

Today, Clover Health, an innovative technology company improving health outcomes for America’s seniors, announced it joined a group of the largest insurers in the United States as a part of the U.S. Food and Drug Administration’s (FDA) Early Payor Feedback Program

SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Medica published an exclusive, positive iFuse coverage policy effective August 19, 2020.

Researchers at the Barbara Ann Karmanos Cancer Institute have secured a one-year, $630,000 grant from the National Cancer Institute (NCI) that will help support the institute’s clinical trials targeting underserved populations in Detroit and in the rural areas that Karmanos serves.

Ligand OmniAb ® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis IMVT-1401 is a novel anti-FcRn OmniAb-derived antibody delivered by subcutaneous injection Registration-enabling Phase 3 trial expected to initiate in the first half of 2021 SAN DIEGO--( BUSINESS WIRE )-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, I

National Health Investors (NYSE:NHI) announced that senior management will be conducting virtual meetings with institutional investors as part of the BMO 2020 Real Assets Conference on Wednesday, September 2, 2020.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, was recently named one of the 100 Best Companies to Work For, a list curated by Seattle Business Magazine, based on employee survey responses.